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Rotavirus (RV) causes morbidity and mortality among infants worldwide, and there is 
evidence that probiotics and prebiotics can have a positive influence against infective 
processes such as that due to RV. The aim of this study was to evidence a preventive 
role of one prebiotic mixture (of short-chain galactooligosaccharide/long-chain fructool-
igosaccharide), the probiotic Bifidobacterium breve M-16V and the combination of the 
prebiotic and the probiotic, as a synbiotic, in a suckling rat double-RV infection model. 
Hyperimmune bovine colostrum was used as protection control. The first infection was 
induced with RV SA11 and the second one with EDIM. Clinical variables and immune 
response were evaluated after both infections. Dietary interventions ameliorated clinical 
symptoms after the first infection. The prebiotic and the synbiotic significantly reduced 
viral shedding after the first infection, but all the interventions showed higher viral load 
than in the RV group after the second infection. All interventions modulated ex vivo 
antibody and cytokine production, gut wash cytokine levels and small intestine gene 
expression after both infections. In conclusion, a daily supplement of the products 
tested in this preclinical model is highly effective in preventing RV-induced diarrhea but 
allowing the boost of the early immune response for a future immune response against 
reinfection, suggesting that these components may be potential agents for modulating 
RV infection in infants.
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inTrODUcTiOn
Rotavirus (RV) is the most common etiological agent of severe dehydrating diarrhea among chil-
dren under the age of 5 worldwide (1). The global median RV detection proportion in hospitalized 
children <5  years of age with acute gastroenteritis (diarrhea) caused by RV was of about 38% 
in 2012 (2), whereas a range of about 215,000 deaths in 2013 were estimated in this context (3). 
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The main symptoms are fever, vomiting, and diarrhea in chil-
dren, for 3–8 days (4, 5). Virtually every child in the world will 
be infected with RV in the first 3 years of life (6), and several 
reinfections usually occur, although they tend to be less severe 
than the first infection (5). RV belongs to the Reoviridae fam-
ily and is a non-enveloped, icosahedral, double-stranded RNA 
covered by a triple layer of capsids. Its viral genome encodes 
for six structural (VPs) and six non-structural proteins (4, 7–9). 
RVs are classified in groups (A–G), subgroups (I and II) and 
serotypes/genotypes (based on the antigenic differences among 
the external capsid). RVs from group A are the main human 
pathogens, and their transmission is fecal-oral, with a higher 
prevalence in the winter season. They infect mature enterocytes 
of the small intestine, but the entry mechanism and pathogenesis 
is still not well known (10, 11).
After RV infection, the innate and adaptive immune responses 
are induced and will lead to the production of cytokines and 
RV-specific antibodies (12, 13). Natural killer lymphocytes and 
dendritic cells are crucial for response activation of both innate 
and adaptive immunity (14). Besides T-cell action on infected 
cells and cytokine production, antibody production by B-cells 
at local and systemic level is required for long-term protection, 
especially IgA (15–18). However, immunity after an RV infection 
is not fully complete and reinfections usually occur, although they 
are less severe than the first infection (5).
Several interventional approaches can be addressed because 
oral rehydration, the most common treatment (19, 20) is not 
sufficient and immune modulatory interventions such as vacci-
nation or dietary supplementation with active agents need to be 
included. In this regard, two live attenuated oral vaccines, Rotateq 
(Merck & Co., PA, USA) and Rotarix (GSK Biologicals, Rixensart, 
Belgium), have been available since 2006. RV vaccines have dem-
onstrated safety and efficacy (2, 3, 7, 21), but their implementation 
is not yet global (6, 20). With regard to nutritional interventions, 
bioactive components from breast milk, which are found in high 
proportions in colostrum, probiotics or prebiotics are the leading 
studied products.
Thus far, whey protein concentrates and bovine colostrum 
(with or without RV-specific antibodies) have shown effective 
protection against RV disease (22–28), and thus are candidates 
for protection control in dietary interventional studies. Moreover, 
a colostrum from cows immunized with a RV strain and therefore 
with high anti-RV-Ab titers [hyperimmune bovine colostrum 
(HBC)] has also been tested in different RV-infection models 
with very satisfactory results (25, 26).
Probiotics are live microorganisms that, when administered 
in adequate amounts, confer a health benefit on the host (29). 
Several species of the Lactobacillus and Bifidobacterium genera 
have been studied and have demonstrated some positive effects 
against RV infection by modulating several mechanisms: chloride 
secretion and oxidative stress (30), virus replication and adhesion 
capacity (31, 32), and host immune cell response (33). Due to 
these actions, probiotics have led to clinical amelioration in ani-
mal models (34, 35), as well as some clinical and immunological 
benefits in RV-infected babies in clinical trials (36–39). On the 
other hand, prebiotics are indigestible food ingredients that reach 
the colon and promote the growth or activity of certain beneficial 
species in the intestinal microbiota, thereby generating a health 
benefit (40, 41). Besides their beneficial role in modulating short-
chain fatty acids (SCFAs) or even intestinal IgA secretion (41), 
only a few interventional studies have been conducted to investi-
gate the role of prebiotics against RV infection. However, because 
of their importance in early life, such as through human milk 
oligosaccharides or specific mixtures of short-chain galactooli-
gosaccharides (scGOSs) and long-chain fructooligosaccharides 
(lcFOSs), which are widely used in infant formulas, prebiotics 
have been studied most in both preclinical (42, 43) and clinical 
(44, 45) studies involving RV infection.
In previous studies, the effectiveness of a prebiotic mixture, 
scGOS/lcFOS, in a proportion of 9:1 (Nutricia Research, The 
Netherlands), with or without the probiotic Bifidobacterium breve 
M-16V, and the probiotic B. breve M-16V alone, has been tested 
in an RV-infected neonatal rat model (43). However, one of the 
limitations of these studies was that the frequency of reinfection 
in humans is very high, and the impact of these active compounds 
on the host immunity against a new RV infective process is 
not known. A double-infection model will provide significant 
information on how the protection against the first infection due 
to the prebiotic or probiotic interventions will affect the second 
infection, mainly in terms of immune response. For that reason, 
a rat double-RV infection model has been used to study this type 
of effect due to interventional approaches in early life.
In light of the above comments, the hypothesis of this study 
is that the modulation of first infection by microbial modulator 
components may regulate the onset of a future reinfection. Thus, 
the aim of this study was to test the effectiveness of a prebiotic 
mixture, scGOS/lcFOS (9:1), with or without the probiotic 
B. breve M-16V, and the probiotic B. breve M-16V alone, in a 
double-RV infection neonatal rat model.
MaTerials anD MeThODs
animals
Twenty-four G14 pregnant Lewis rats (LEW/Han®Hsd) were 
obtained from Harlan (Horst, The Netherlands). They were 
housed individually in cages (2184L Eurostandard Type II L, 
Tecniplast, West Chester, PA, USA) with large fibrous particles 
bedding and tissue papers as enrichment and, monitored daily 
and allowed to deliver at term. The day of birth was registered as 
day 1 of life. Litters were unified to seven pups per lactating dam 
with similar number of each sex in each nest. The pups had free 
access to the nipples (until PN16) and the rat diet. The animals 
were housed in controlled temperature and humidity conditions, 
in a 12:12 h light/dark cycle. They were located in a special safe, 
isolated room at the Animal Service of the Faculty of Pharmacy, 
University of Barcelona, designed and authorized for working 
under biosecurity level 2 conditions. The dams were fed with a 
commercial diet (Teklad Global Diet 2014, Envigo, Indianapolis, 
IN, USA) corresponding to the American Institute of Nutrition 
93G formulation (46) and given water ad libitum.
All experimental procedures were conducted in accordance 
with the institutional guidelines for the care and use of labora-
tory animals and were approved by the Ethical Committee for 
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Animal Experimentation of the University of Barcelona and 
the Catalonia Government (CEEA-UB Ref. 493/12, DAAM: 6905), 
in full compliance to national legislation following the EU- 
Directive 2010/63/EU for the protection of animals used for 
scientific purposes.
Viruses
Two different type A viruses were used for the experiments: sim-
ian agent 11 (SA11) and the epizootic diarrhea of infant mouse 
virus (EDIM). The virus selected for the first infection was the 
SA11, an RV strain produced by the “Enteric Virus Group” of the 
University of Barcelona, as used in previous studies (23, 43, 47). 
The virus selected for the second infection was the EDIM, obtained 
in vivo from inoculated neonatal BALB/c mice (Janvier, La Plaine 
Saint Denis Cedex, France) with an initial inoculum of the virus 
(Nutricia Research, the Netherlands). Briefly, stool samples were 
collected twice a day from day 3 to day 13, pooled and homog-
enized by using Polytron® (Kinematica, Luzern, Switzerland). 
EDIM was extracted with Genetron® (1,1,2-trichloro-1,2,2-trif-
luoroethane, Sigma-Aldrich, Madrid, Spain) and later quantified 
by ELISA as described in previous studies (26).
experimental Design and Dietary 
supplementation
Suckling rats were distributed into following six different 
experimental groups: reference (REF), double rotavirus infection 
(DRI), hyperimmune bovine colostrum (HBC), prebiotic (PRE), 
probiotic (PRO), and synbiotic (SYN).
Each group was composed of three litters of seven pups each 
(n = 21/group). The dietary intervention was orally administered 
to the animals as previously described (48), using low-capacity 
syringes (Hamilton Bonaduz, Bonaduz, Switzerland) adapted 
to 25- or 23-caliber forced alimentation tubes, 27 mm in length 
(ASICO, Westmont, IL, USA), with the different products (HBC, 
PRE, PRO, and SYN groups) or vehicles (DRI and REF groups) 
from day 3 until day 14 of life. The HBC group received 50 mg/
animal/day of “anti-RV hyperimmune bovine colostrum”; this 
HBC was tittered to be effective in blocking the virus in vitro in 
concentrations higher than 10 µg/mL (gently given by Dr. Viviana 
Parreño, Institute of Virology, CICV and A-INTA, Castelar, 
Argentina). The PRE supplement consisted of a combination of 
scGOS and lcFOS, in a 9:1 ratio (Nutricia, The Netherlands), and 
was administered in a dose of 0.8/100 g of body weight/day. The 
PRO group received B. breve M-16V (Morinaga Milk Industry Co., 
Ltd., Tokyo, Japan) suspension in a dose of 4.5 × 108 UFC/100 g 
of body weight/day. The SYN group received both PRE and PRO 
products in the same concentrations as when administered alone. 
A group of rats receiving bottled mineral water as vehicle was 
the inoculated control group (DRI group), while another group 
receiving water acted as the non-inoculated control group (REF 
group).
The RV inoculations were carried out in all the experimen-
tal groups, with the exception of the REF group, as previously 
described (47). They were done 1 h after separation from their 
dams to avoid interference between RV and milk components 
following previous procedures from the group (23, 43, 47). This 
action is required due to the presence of human breast milk 
components that can block the virus and reduce its infection 
such as oligosaccharides or maternal antibodies (49). SA11 was 
selected as the first infective virus because previous studies allowed 
us to obtain a rat model of mild diarrhea in early life (23, 43, 47). 
It was orally inoculated at day 6 of life in a dose of ~2 × 108 TCID50 
RV/rat in 100  µL of phosphate-buffered solution (PBS). EDIM 
was used as the second infective virus, inoculated at day 17 in a 
dose of ~1.3 × 108 RV/mL in 100 µL, when the intestinal immune 
system was still in maturation (50). Furthermore, because of the 
importance of the bioactive factors present in maternal milk in 
protecting the pups from infection, the weaning day was on day 
16, to induce a lower defensive situation in the pups. In addition, 
there were two more groups: those infected singly either with 
SA11 (SA11) or with EDIM. Moreover, selected animals from the 
supplemented groups were not submitted to the second infection 
with EDIM and therefore preliminary data from animals infected 
singly with SA11 and with dietary interventions (SA11 + HBC, 
SA11 + PRE, SA11 + PRO, and SA11 + SYN) were also obtained 
at the end of the study.
Clinical evaluation was performed daily from the first day 
of supplementation (day 3) until the end of the study (day 28). 
One-third of the animals from each group were euthanized on 
day 16 of life, and the rest on day 28. Fecal samples were collected 
daily during the study, and blood, small intestine, intestinal wash 
samples, small intestinal tissue and isolated spleen, and mesen-
teric lymph node (MLN) cells at the end point. Body temperature 
and fecal pH were measured during the peri-inoculation period 
of both infections. The delayed-type hypersensitivity (DTH) 
response was determined at the end of the study.
The animals were weighed and monitored daily during the 
early light phase to obtain data regarding the influence of the 
virus inoculation, clinical development and nutritional interven-
tion on growth and fecal features. This was done after separation 
of the pups from their mother, during the handling and before 
oral administration; the whole litter together was reunited with 
the dam after interventional actions.
clinical indexes and Fecal specimen 
collection
SA11 and EDIM infections were evaluated from day 2 to day 28 
of life by the growth rate and clinical indexes that require daily 
fecal sampling as previously described (47). Briefly, fecal sam-
pling was performed once a day by gently pressing and massaging 
the abdomen. Specimens were immediately scored for severity of 
diarrhea, weighed and frozen at −20°C for further analysis. The 
severity of diarrhea was expressed by the fecal weight and by scor-
ing stools from 1 to 4 [diarrhea index (DI)] based on color, texture 
and amount as follows: normal (DI =  1), loose yellow-green 
(DI = 2), totally loose yellow-green (DI = 3), and high amount 
of watery (DI = 4) feces. Diarrhea scores ≥ 2 indicate diarrheic 
feces whereas scores of DI < 2 indicate absence of diarrhea. The 
area under the curve of severity (sAUC) during 0–6 DPI was 
calculated as a global value of severity. The maximum diarrhea 
index (MDI) was defined as the highest score during the diarrhea 
period (DP). Incidence of diarrhea was expressed by the percent-
age of diarrheic animals (%DA, consisting of the percentage of 
diarrheic animals taking into account the number of animals 
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in each group) and by the percentage of diarrheic feces (%DF, 
consisting of the percentage of diarrheic samples taking into 
consideration the number of total samples collected every day in 
each group). The AUCs of %DA and %DF (daAUC and dfAUC) 
during 0–6 DPI were calculated as a global value of incidence. 
The AUCs for severity, %DA and %DF were also calculated taking 
into account the basal values due to intrinsic aspects of each treat-
ment (normalized AUC). The maximum percentages of diarrheic 
animals (MDA) and diarrheic feces (MDF) were defined as the 
highest values during the DP. The days when MDI, MDA, and 
MDF were achieved were also used as indicators, called MDId, 
MDAd, and MDFd, respectively. The DP was calculated for each 
animal as the interval between the first [day of diarrhea beginning 
(DDB)] and last [day of diarrhea ending (DDE)] day of diarrhea. 
The actual days with diarrhea (DwD) within the DP were also 
counted (DwD).
Fecal ph Determination
Fecal samples from the peri-inoculation period of the virus were 
diluted in distilled water (up to 200 mg/mL) and gently agitated. 
Their pH was measured using a 5207 pH electrode for surfaces 
(Crison Instruments, Barcelona, Spain) and a micropH 2001 pH 
meter (Crison Instruments).
Body Temperature Determination
The rats’ body temperature was measured with a TEMP JKT 
thermometer (Oakton, Vernon Hills, IL, USA) and an RET-3-ISO 
rectal probe for neonatal rats (Physitemp, Clifton, NJ, USA) and 
with the aid of peanut oil (Acofarma, Terrassa, Spain) to lubricate. 
This measure was taken 1–2 days before the inoculation of the 
virus (initial temperature) and 1–2 days after inoculation of the 
virus (final temperature). Results were expressed as the absolute 
increase in temperature taking into account the final temperature 
(after RV inoculation) with respect to the initial temperature 
(before RV inoculation).
Viral shedding
Fecal samples from selected days of interest were diluted in PBS 
(10 mg/mL) and homogenized using a FastPrep (MP Biomedicals, 
Santa Ana, CA, USA). Homogenates were centrifuged (19,000 g, 
3 min), and supernatants were frozen at −20°C until use. SA11 
and EDIM particles in fecal samples were quantified by ELISA, as 
previously described (47). Titrated dilutions of inactivated SA11 
virus particles, ranging from 4 × 105 to 2.5 × 104/mL, were used 
as standard in each plate.
DTh response
Two days before sacrifice (day 26), the thickness of both the right 
and left ears of every animal was measured to constitute the basal 
conditions by using a 7309 pocket thickness gauge (Mituyoto, 
Hampshire, UK). For virus priming, animals were anesthetized 
with isoflurane (Abbott Laboratories, Berkshire, UK), and the 
virus was injected into the ear using low-volume Hamilton 
syringes (100 µL) connected to needles (30 G 1/2 0.3 × 13). A 
volume of 20 µL of UV-inactivated virus (~0.5 × 106 RV particles/
mL) was injected into the right ear (RE), and the same volume of 
PBS was injected into the left ear (LE). After 24 and 48 h, before 
sacrifice, an evaluation of the ear thickness was performed again. 
Results are expressed as the increase in thickness of the RE minus 
the increase in thickness of the LE (to eliminate the intrinsic 
increase due to the puncture).
Blood, spleen, and intestinal sample 
collection
After previous anesthesia with intramuscular ketamine/xylazine 
injection (Imalgene 100 mg/mL, Merial Laboratorios, Barcelona, 
Spain/Rompun® 20  mg/mL, Bayer Hispania, Sant Joan Despí, 
Spain), rats from each group were euthanized at days 16 or 28 
by opening the peritoneal cavity and disrupting the diaphragm. 
Blood was collected by cardiac puncture, and after centrifuga-
tion sera was stored at −20°C until analysis. The small intestine 
was weighed, cut into 5 mm pieces and incubated with PBS for 
10 min at 37°C in a shaker to obtain the gut wash (GW). After 
centrifugation, supernatants were stored at −80°C until analysis. 
One centimeter of tissue from the middle of the small intestine 
was obtained and kept in RNAlater from Ambion (Thermo Fisher 
Scientific, Barcelona, Spain) at −20°C for further determinations. 
The spleen and MLNs were removed under sterile conditions. 
Spleen and MLN cells were isolated as previously described (51). 
Cell numbers and viability were determined using an automated 
cell counter after staining dead cells with trypan blue (Countess™, 
Invitrogen, Madrid, Spain). Isolated mononuclear cells from the 
spleen and MLNs were cultured for 72 h under SA11/EDIM mix 
stimulatory conditions (105 viral particles/mL). After incubation, 
the 24-well plate was centrifuged, and the supernatants were col-
lected and kept at −80°C until cytokine determination.
elisa for Total iga and igM antibody 
Quantification in serum and gW
Ninety-six-well plates (Nunc MaxiSorp, Wiesbaden, Germany) 
were coated with purified mouse anti-rat IgA or IgM (BD 
Biosciences, Heidelberg, Germany). After blocking with PBS-
1% bovine serum albumin [BSA, 1 h, room temperature (RT)], 
appropriate diluted sera or intestinal wash samples were added 
(3  h, RT). After washing, biotin anti-rat IgA or IgM from BD 
Biosciences, followed by peroxidase-conjugated extravidin 
(Sigma-Aldrich), were added. Subsequently, substrate was added, 
as previously described (47). Dilutions of purified rat IgA or IgM 
(BD Biosciences) ranging from 80 to 1.25 ng/mL were used as 
a standard in each plate. Quadratic polynomial adjustment was 
used.
elisa for specific anti-rV Total and igM 
antibody Quantification in serum and gW
Ninety-six-well plates (Nunc MaxiSorp) were coated with 
UV-inactivated SA11 particles at 105/mL. After blocking with 
PBS-1% BSA (1 h, RT), appropriate diluted sera or intestinal wash 
samples were added (3 h, RT). After washing, rabbit anti-rat Ig 
conjugated to peroxidase from Dako (Barcelona, Spain) or mouse 
biotinylated anti-rat IgM (G53-238) monoclonal antibody from 
BD Biosciences, followed by peroxidase-conjugated extravidin 
(Sigma-Aldrich), were added. Subsequently, substrate was added, 
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as previously described (47). Pooled sera from dams of inoculated 
litters were used as a standard in each plate. Quadratic polynomial 
adjustment was used.
elisPOT for specific anti-rV antibody 
Production
An ELISPOT technique was used to quantify anti-RV Ig-secreting 
cells (SC) from spleen and MLN by following previous experience 
(52). Ninety-six-well nitrocellulose plates (Merck Millipore) were 
coated with viral particles of SA11 or EDIM (105 particles/mL) 
in sterile conditions (overnight, 4°C). The remaining binding 
sites were blocked with complete media for 1 h at 37°C. Freshly 
isolated cells were plated at serial dilutions (2 ×  105, 1 ×  105, 
0.5 ×  105, and 0.25 ×  105 cells/well) and incubated for 3  days 
(37°C, 5% CO2). Cells were then removed by washing 10 times 
with PBS containing 0.25% of Tween 20, and once with distilled 
water. Biotin-conjugated anti-rat IgM Ab (BD Pharmingen, San 
Diego, CA, USA, 2 mg/L in PBS) was added and incubated for 2 h. 
The plate was washed again, and then incubated with extrAvidin-
peroxidase conjugate (Sigma-Aldrich, 4 mg/L) for 1 h. Spots, each 
one corresponding to one anti-RV Ig-SC, were visualized after 
adding the substrate solution (3-amino-9-ethyl-carbazole plus 
H2O2 in 0.1  mol/L acetate solution). The reaction was stopped 
using tap water. Spots were counted automatically by computer-
assisted ELISPOT image analysis (ELISPOT reader system, AID, 
Strasberg, Germany) and expressed as the number of Ig-SC per 
106 cells.
Bead immunoassay
The cytokine concentration in supernatants from stimulated 
spleen cells and from GW samples was measured. Antiviral 
and Th1 (IFNγ), Th2 (IL-4), anti-inflammatory and regula-
tory (IL-10), and pro-inflammatory (TNFα) cytokines were 
evaluated. Molecule determinations were performed using a 
BD™ Cytometric Bead Assay Rat Soluble Protein Flex Set (BD 
Biosciences, Madrid, Spain) as detailed in previous studies (53). 
A FacsAria SORP sorter (BD, San José, CA, USA) from the 
cytometry service of the Scientific and Technological Centers of 
the University of Barcelona (CCiT-UB) was used. Data analysis 
was performed using the FlowJo 10.0.7 software (Tree Star, Inc., 
Ashland, OR, USA).
real-Time Pcr for small intestine gene 
expression
Gene expression of different genes that could be of interest was 
evaluated. Specifically, we selected target genes expressed in the 
small intestine at day 28 that could be representative of the pos-
sible effect that the dietary intervention could modulate: recep-
tors from the TLR family (i.e., TLR2 and TLR4), Th1 and Th2 
responses (IFNγ and IL-4, respectively), molecules involved in 
the Tight Junction (TJ, i.e., Occludin, Claudin-2), innate defenses 
(mucin), and regulatory and tolerogenic response (IL-10, TGF-β, 
and FoxP3).
On sacrifice day, the intestinal tissue was obtained and 
kept in RNAlater from Ambion (Thermo Fisher Scientific) at 
−20°C until analysis. Homogenization was performed by using 
lysing matrix tubes (MP Biomedicals, Illkirch, France) in a 
FastPrep-24 instrument (MP Biomedicals). RNA was isolated 
with the RNeasy® Mini Kit (Qiagen, Madrid, Spain) following 
the manufacturer’s instructions as previously described (54). A 
Nanodrop spectrophotometer and Nanodrop IVD-1000 v.3.1.2 
software (Nanodrop Technologies, Wilmington, DE, USA) 
were used to quantify the amount and purity of RNA obtained. 
The RNA integrity number was evaluated, using the Genomic 
Service of the SCT-UB, to ensure the quality and integrity of the 
material. RNA was reverse-transcribed, as previously described 
(54). PCR Taqman® primers and probes specific for rat target 
genes and HPRT as endogenous control were used (Assays on 
Demand™, Gene Expression Products, AB). The amount of 
target mRNA, normalized with an endogenous control (HPRT) 
and relative to a calibrator (tissue samples from the REF group 
as the control group), was given by the 2−ΔΔCt method, as previ-
ously described (54). Results are expressed as the mean ± SEM 
of the percentage of these values for each experimental group 
compared with its reference group, which represents 100% of 
gene expression.
short-chain Fatty acids
The production of acetic, propionic, formic, lactic, and butyric 
acids in the fecal samples were determined by HPLC (Merck) 
equipped with RI detection. The column used was an ion-exclusion 
REZEX-ROA organic acid column (Phenomenex Inc., UK), and 
temperature maintained at 84°C. Sulfuric acid in HPLC-grade 
H2O (0.0025 mmol/L) was used as the eluent, and the flow rate 
was maintained at 0.5 mL/min. Aliquots of 300 mg (w/v) of feces 
collected in microcentrifuge tubes were centrifuged at 13,000 g 
for 10 min to remove all particulate matter. The fecal supernatants 
were then filtered using 0.22 µm low protein binding Durapore 
polyvianylidene fluoride membranes (Millex; EMD Millipore, 
Billerica, MA, USA) to remove possible bacteria. 50 µL of each 
sample was injected with a run of 45 min into HPLC. Peaks were 
integrated using the Atlas Lab managing software (Thermo Lab 
Systems, Mainz, Germany). Quantification of the samples was 
obtained through calibration curves of acetic, propionic, formic, 
lactic, and butyric acids in concentrations ranging between 12.5 
and 100 mM.
statistical analysis
Taking into account the number of pups as statistical unit, the 
number of animals used in each group for detecting a statistically 
significant difference among groups assuming that there is no 
dropout rate and type I error of 0.05 (two-sided) was calculated 
by the Appraising Project Office’s program from the Universidad 
Miguel Hernández de Elche (Alicante). The variables used for the 
calculation included both the clinical outcomes, particularly the 
severity score, and immune variables, by means of the anti-RV 
Ig levels. Moreover, as previous studies demonstrated the impor-
tance of the litter effect (23, 43, 47), independently of the number 
of animals obtained above, at least three litters were required for 
each group. Taking this into account, three litters of seven animals 
per group were enough for the sample-size estimation performed. 
The final number of animals was not affected by the dropouts or 
outliers, which did not occur in this study.
FigUre 1 | Body weight (g) during the study, before, and after the virus inoculations (indicated by arrows) on day 6 and day 17 (a) for REF, DRI, and HBC groups; 
(B) for DRI, PRE, PRO, and SYN groups. Results are expressed as mean values ± SEM. Statistical significance is explained in the text (n = 12–21 animals/group). 
Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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The PASW Statistics 22 software package (SPSS Inc., Chicago, 
IL, USA) was used for the statistical analysis. The Kolmogorov–
Smirnov test was applied to assess normal distribution, followed 
by Levene’s test to determine variance equality. A conventional 
one-way ANOVA test was performed taking the experimental 
group as the independent variable. When virus inoculation or 
dietary interventions had a significant effect on the dependent 
variable, Scheffé’s post hoc test was applied. The Kruskal–Wallis 
and Mann–Whitney U tests were used when non-normal distri-
bution or different variance was found. Finally, the chi-square test 
was used to compare frequencies. Differences were considered 
significant at p values of < 0.05. All the results are expressed as 
mean ± SEM of a certain number of animals.
resUlTs
Body Weight
Body weight was recorded between days 2 and 28 of life. The 
former was about 6–7  g and the latter about 44–49  g. As can 
be seen in Figure 1, the inoculation with the first virus (SA11) 
was performed on pups with a body weight of around 10–11 g, 
and it had no impact on this variable. With regard to the second 
inoculation with EDIM, a weight loss was observed on day 17 
(p < 0.01). However, it cannot be ascribed to the infection but 
is due to the early weaning, since the REF group showed the 
same pattern. The HBC intervention did not induce changes in 
the body weight course compared with the REF and DRI groups 
(Figure 1A).
As regards the effect of dietary supplementation on body 
weight, Figure 1B shows that the prebiotic intervention (PRE) 
induced a slight decrease in the weight of the animals before the 
first inoculation (first week of life) when compared with the REF 
group (p < 0.05). The SA11 inoculation did not affect the growth 
of these animals in the next few days (when compared with REF 
or DRI) because the pattern was similar to before. After day 13, 
the prebiotic group also started to weigh less than the DRI group 
(p <  0.05). The EDIM inoculation did not affect this variable 
either, but the early weaning did cause a loss of body weight as in 
the REF and DRI groups.
The dietary supplementation with the PRO and the SYN 
(Figure  1B) induced a pattern of body weight similar to that 
found for the prebiotic administration. During life, the animals 
from the PRO group had a lower body weight than those from the 
REF and the DRI groups (p < 0.05), although this difference was 
not so evident for the animals in the SYN group. The same body 
weight loss after early weaning (day 17) was again observed, but 
there was no effect due to SA11 or EDIM inoculation.
When the global behavior during the post-infective period 
was studied after the first RV inoculation, the percentage of 
body weight increase between day 7 and day 17 in all groups was 
between 123 and 155%, with all the inoculated animals’ values 
being higher than those from the REF group (p < 0.05). After the 
second infection with EDIM (day 17–27), no differences among 
groups were found.
incidence of Diarrhea
As can be seen in Figure 2, diarrhea appeared only after the first 
infection (day 6 with SA11), and not after the second (day 17 with 
EDIM), as was expected. Focusing on the former, the incidence of 
SA11-induced diarrhea was evaluated by two approaches whose 
results were very similar: the %DA (diarrheic feces in the total 
animals) or %DF (diarrhea in the total obtained feces). With 
regard to the %DA, in the DRI group it was about 27% on 1 DPI 
(Figure 2A); it increased up to 60% on 2 and 3 DPI, and achieved 
the maximum value of 87% on 4 DPI (day 10 of life). Later, on 5 
DPI, it decreased to 7%, and on day 6 DPI none of the animals in 
the DRI group had diarrhea (Figure 2A). The inoculation of EDIM 
on day 17 did not induce any modification in the fecal appearance 
during the following days and until day 28 (Figure 2A). When the 
diarrhea incidence was studied in supplemented animals, all the 
groups showed a modulatory effect: all supplemented groups had 
lower %DA than the DRI group over the 3–4 DPI period (days 
FigUre 2 | Clinical indexes. Incidence of diarrhea (a) for REF, DRI, and HBC groups; (B) for DRI, PRE, PRO, and SYN groups. Results are expressed as % of 
diarrheic animals. Severity of diarrhea (c) for REF, DRI, and HBC groups; (D) for DRI, PRE, PRO, and SYN groups: fecal samples are scored from 1 to 4 based on 
color, texture, and amount of stool. Scores on diarrhea index ≥ 2 indicate diarrheic feces. The inoculation days are indicated by arrows. Results are expressed as 
mean ± SEM. Statistical differences mentioned in the text (n = 12–21 values/group). Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune 
bovine colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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9 and 10 of life, p < 0.05). The HBC group was totally protected 
throughout the study period (Figure 2B).
As can be seen in Figure 2B, the PRE induced a certain %DA 
even before the SA11 inoculation (20–45%) and throughout the 
nutritional intervention period. However, the MDA in this group 
was 50% (Table 1), achieved on day 7 and much lower than the 
87% in the DRI group (p < 0.01), and the %DA on days 9 and 10 
(the highest in the DRI group) was reduced by up to 15 and 40%, 
respectively (p < 0.05).
Figure 2B shows %DA from those groups receiving the PRO 
and SYN supplement. PRO only induced a clear %DA after SA11 
inoculation, with this value always being lower than that of the 
DRI group. It should be highlighted that the MDA in this group 
was 36% (Table 1), achieved on day 8 and much lower than the 
87% of the DRI group, and that the %DA during days 7–11 was 
statistically lower as well (p < 0.05).
The SYN induced a certain %DA before and after the SA11 
inoculation in a similar way to PRE but achieved higher values 
(30–60%). The MDA in this group was 70% on day 8 (p < 0.05 vs. 
DRI group), and the %DA during days 9 and 10 was reduced to 
23 and 30%, respectively (p < 0.05 vs. DRI group).
Thus, before and after the SA11 infection the PRE and SYN 
diets induced changes in the fecal consistency, increasing the 
number of feces considered diarrheic. To better dissect this direct 
effect, already described for certain prebiotics, a normalization of 
the results was performed on the basis of the average punctuation 
of the products obtained in the period before infection (day 3–6), 
and after the infection was ended (day 12–16). This procedure has 
been shown to be similar to that performed using data from a non-
infection study (43). After normalization of the data, the effect of 
PRE and its combination with the probiotic in terms of incidence 
(both %DA and %DF) was even more evident (Table 1; Figure 3).
When the AUC of %DA was calculated (daAUC, Table 1), it could 
be seen that all the supplemented groups, with the exception of the 
SYN group, presented a lower value than the DRI group (p < 0.05). 
By contrast, the daAUC for the SYN group was higher than that in 
FigUre 3 | Normalized clinical indexes. (a) Normalized incidence of diarrhea for DRI, PRE, PRO, and SYN groups: results are expressed as % of diarrheic animals. 
(B) Normalized severity of diarrhea for DRI, PRE, PRO, and SYN groups: fecal samples are scored from 1 to 4 based on color, texture, and amount of stool. Scores 
on diarrhea index ≥ 2 indicate diarrheic feces. The inoculation days are indicated by arrows. Results are expressed as mean ± SEM. Statistical differences 
mentioned in the text (n = 15–21 values/group). Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine colostrum; PRE, prebiotic; PRO, 
probiotic; SYN, synbiotic.
TaBle 1 | Clinical variables determining the diarrhea process (from day 0 to 6 DPI).
reF Dri hBc Pre PrO sYn
incidence MDa 0.00 86.67 0.00# 50.00# 35.71# 69.23#
MDad – 10 – 7 8 8
daaUc 0.00 225.00 0.00 192.50 100.00 245.80
daaUcn 0.00 225.00 0.00 92.50 100.00 89.16
MDF 0.00 100.00 0.00# 100.00 38.46# 81.82#
MDFd – 9 – 7 8 8
dfaUc 0.00 368.96 0.00 376.03 122.90 425.63
dfaUcn 0.00 368.96 0.00 167.50 122.90 184.89
Duration DDB – 8.2 ± 0.3 – 7.7 ± 0.3 8.0 ± 0.2 7.4 ± 0.4
DDe – 9.9 ± 0.1 – 11.0 ± 0.4# 8.8 ± 0.4# 10.2 ± 0.7
DP 0.0 ± 0.0 2.7 ± 0.3* 0.0 ± 0.0# 3.6 ± 0.5* 1.1 ± 0.3*,# 3.5 ± 0.7*
DwD 0.0 ± 0.0 2.4 ± 0.2* 0.0 ± 0.0# 2.2 ± 0.3* 1.0 ± 0.3*,# 2.9 ± 0.7*
severity MDi 1.05 ± 0.03 2.60 ± 0.11* 1.15 ± 0.05# 2.58 ± 0.11* 2.14 ± 0.22* 2.53 ± 0.19*
MDid – 8.40 ± 0.27 – 8.61 ± 0.42 8.33 ± 0.22 8.60 ± 0.54
saUc 0.03 ± 0.02 3.46 ± 0.22* 0.25 ± 0.09*,# 3.27 ± 0.39* 2.29 ± 0.37*,# 4.00 ± 0.92*
saUcn 0.03 ± 0.02 3.46 ± 0.22* 0.25 ± 0.09*,# 2.28 ± 0.30*,# 2.29 ± 0.37*,# 2.69 ± 0.72*
With regard to incidence: MDA, maximum percentage of diarrheic animals; MDAd, day with maximum percentage of diarrheic animals; daAUC, area under the curve of diarrheic 
animals; daAUCn, normalized area under the curve of diarrheic animals; MDF, maximum percentage of diarrheic feces; MDFd, day with maximum percentage of diarrheic feces; 
dfAUC, area under the curve of diarrheic feces; dfAUCn, normalized area under the curve of diarrheic feces.
With regard to duration: DDB, day of diarrhea beginning (DPI); DDE, day of diarrhea ending (DPI); DP, diarrhea period; DwD, days with diarrhea.
With regard to severity: MDI, maximum diarrhea index; MDId, day of maximum diarrhea index (DPI); sAUC, area under the curve of severity; sAUCn, normalized  
area under the curve of severity.
Results are expressed as mean ± SEM (n = 12–21 animals/group).
Statistical differences: *p < 0.05 vs. REF; #p < 0.05 vs. DRI.
Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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the DRI group (p < 0.05). However, when the daAUC was normal-
ized by calculating the AUC of the increment of incidence during 
SA11 infection from the baseline of each group (without counting 
the non-pathogenic “diarrhea” induced by the prebiotics in the PRE 
and SYN groups), it was significantly lower (p < 0.05).
When the incidence data were calculated by using the second 
approach, results corresponding to the incidence of diarrheic 
feces (%DF) (Table  1), and their consequent parameters, i.e., 
MDF, MDFd, dfAUC, and dfAUCn, showed the same pattern as 
for the %DA.
Duration of Diarrhea
With regard to the duration of the diarrhea process, in the DRI 
group diarrhea started at day 8.2 ±  0.3 (DDB) and ended at 
day 9.9 ±  0.1 (DDE). The DP and the DwD were 2.7 and 2.4, 
respectively (Table 1). The PRE and SYN diets did not modify 
FigUre 4 | Fecal weight (mg) during the acute diarrhea period (pooled data 
from 1 to 4 DPI samples). Results are expressed as mean ± SEM (n = 32–49 
samples/group). Statistical significance: *p < 0.05 vs. REF, #p < 0.05 vs. DRI. 
Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune 
bovine colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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these variables, but PRO was able to reduce both DP and DwD 
(p < 0.05) (Table 1). It should be emphasized that the PRE and 
SYN groups still had scores >1 until the end of the study and that 
these duration variables are also influenced by the direct effect on 
stool consistency from PRE.
severity of Diarrhea
An effect on stool consistency was only found after SA11 first 
infection, and not after EDIM infection on day 17, or a combina-
tion of both (DRI) during the second infection. With regard to the 
first infection, as can be seen in Figure 2C, the severity curve in 
the DRI group increased from day 7 (1 DPI) and was maintained 
at similar values until day 10 (4 DPI). At day 11, the mean score 
was under 2, and therefore it is not likely that the animals had 
diarrhea. Afterward, no animals from this group had signs of 
diarrhea and had a DI = 1. This diarrhea was totally prevented 
by the HBC intervention, as can be seen by the low punctuations 
obtained during the process, which were all around 1 (Figure 2C). 
By contrast, the PRE was not able to prevent this clinical variable 
of diarrhea, and the score values were similar to those from the 
DRI group (Figure 2D). The direct effect of this compound on 
fecal texture is evidenced by scores higher than 1 before infec-
tion and after the DP (days 7–12), as previously mentioned. As 
also observed for the incidence and duration variables, the PRO 
intervention was the most effective in reducing the severity of 
diarrhea (p < 0.05 vs. DRI group on days 7, 9, and 10). However, 
when the probiotic is administered with the PRE (SYN group) 
this protective action disappeared (Figure 2D). The effectiveness 
of the PRE and SYN diets in controlling the RV infection could 
not be seen through direct scoring data because the products 
induced features that occulted their putative action. The mean 
MDI for all infected groups was around 3, with the exception of 
that of the HBC group, which was lower (p < 0.05). In all cases, 
it was obtained around day 8 (Table 1). The AUC of the severity 
pattern calculated during the period with diarrhea (Table  1) 
showed AUC values of about 3 in inoculated animals, whereas 
REF animals did not develop diarrhea and had AUC values of 
around 0, along with the HBC group. Interestingly, a significant 
reduction in sAUC was observed for the PRO group with respect 
to the DRI group, demonstrating an overall reduction in the 
severity of the disease (p < 0.05). The PRE group only showed a 
significant reduction in sAUC when it was normalized (from its 
baseline DI present before and after the infective process), and the 
SYN did not modify this variable.
Fecal Weight
The weight of the fecal samples was recorded throughout the 
study. During the acute DP (1–4 DPI), animals from the DRI 
group had a higher fecal weight (~14 mg) than those from the 
REF group (~5 mg) (p < 0.05). The fecal weight from the HBC 
group in this period was significantly lower than that from the 
RV animals (p < 0.05) and similar to that from the REF group 
(~4 mg). The weights of fecal samples from the PRO, PRE, and SYN 
groups were higher than those from the REF group (p < 0.05), 
but all nutritional interventions were able to decrease the fecal 
weight with respect to the DRI group (p <  0.05) (Figure  4). 
Before and after this period, the fecal weight was similar among 
groups, and only the PRE and SYN groups had a slightly higher 
value (data not shown). The infection with EDIM alone on day 
17 did not induce any change in fecal weight. Moreover, in all 
the studied groups, those double-infected without being supple-
mented (DRI) and those after the dietary intervention displayed 
a fecal weight of 27.4 ±  1.0  mg in the 1–4  days post EDIM 
inoculation.
ph changes
The pH of fecal samples from 1 to 5 DPI in each of the two 
infections was measured. With regard to SA11 infection, the DRI 
group showed a higher fecal pH (7.18 ± 0.14) on day 7 (1 DPI) 
than the REF group (mean 5.54  ±  0.44) (p  <  0.05). All the 
nutritional interventions avoided this change and had pH values 
similar to that in the REF group (of about 5.5–6). The value 
of fecal pH one day after the second virus inoculation (EDIM 
on day 17) in the DRI animals (5.73 ± 0.34) was similar to those of 
REF or EDIM groups (5.25 ± 0.25 and 5.42 ± 0.28, respectively), 
and none of the diets caused significant changes in pH either 
(being in all cases of about 5.3–6.1).
Temperature changes
The rats’ body temperature was measured from 0 to 3 DPI for 
both SA11 and EDIM infections as a possible new marker of 
disease. The relative increase in temperature for the maximum 
value obtained after infection with respect to the 0 DPI value 
was calculated for each animal and is shown in Table  2. After 
the first infection with SA11, an increase in rectal temperature 
was observed among the infected animals when compared 
with the REF group (p <  0.05). Even though diarrhea was not 
observed in the group of animals infected only with EDIM at 
day 17, an increase in body temperature was found in this group 
(2.61 ± 0.97°C, p < 0.05 vs. REF group), suggesting the presence 
of infection. However, the presence of the first infection in the 
DRI animals seemed to prevent such an increase when the second 
TaBle 2 | Body temperature increase in the peri-inoculation period (first and 
second infections).
1st infection 2nd infection
REF 0.90 ± 0.29 0.21 ± 0.14
DRI 2.11 ± 0.41* 0.00 ± 0.00
HBC 4.85 ± 1.23* 1.15 ± 0.65
PRE 3.18 ± 0.95* 0.27 ± 0.18
PRO 3.42 ± 0.75* 1.02 ± 0.45
SYN 1.10 ± 0.42 0.40 ± 0.40
Results are expressed as mean ± SEM (n = 12–21 animals/group).
Statistical differences: *p < 0.05 vs. REF.
Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine 
colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
TaBle 3 | Ex vivo anti-rotavirus Ig producing spleen and mesenteric lymph node 
(MLN) cells from 28-day-old animals from SA11 and double-infected (SA11 and 
EDIM) groups with dietary intervention.
sa11 infection sa11 and eDiM infections
spleen Mln spleen Mln
REF 204.7 ± 40.8 245.1 ± 43.9 204.7 ± 40.8 245.1 ± 43.9
DRI 228.0 ± 21.2 318.3 ± 36.3 302.9 ± 18.5* 296.7 ± 29.3
EDIM – – 223.4 ± 34.6 205.5 ± 36.7
HBC 340.0 ± 75.1*,# 443.3 ± 43.3*,# 242.6 ± 51.1 215.1 ± 42.9
PRE 435.1 ± 72.1*,# 188.3 ± 16.4# 253.1 ± 23.4 246.0 ± 26.9
PRO 356.7 ± 114.0*,# 320.0 ± 45.8 174.6 ± 46.0# 216.5 ± 51.9
SYN 396.7 ± 112.7*,# 375.0 ± 62.1*,# 250.9 ± 57.3 276.2 ± 54.8
Results are expressed as mean Ig-SC/106 cells ± SEM (n = 3–12 animals/group).
Statistical differences: *p < 0.05 vs. REF; #p < 0.05 vs. SA11 or DRI.
Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine 
colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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infection was performed. In addition, the double-infected sup-
plemented groups did not experience any effect on temperature 
after the second infection (Table 2).
Viral shedding
In all RV-inoculated animals, the maximum viral shedding was 
observed on the first day after inoculation (1 DPI) for both SA11 
and EDIM infections. Taking day 7 (1 DPI for SA11) into account, 
the HBC group had a similar RV shedding to the DRI group 
(101.36% with respect to the DRI group’s viral shedding). The 
PRO group showed a viral clearance of 135.82% compared with 
that of the DRI group. By contrast, the PRE and SYN groups had 
a lower viral shedding than the DRI group (59.33 and 57.70%, 
respectively, p < 0.05).
As regards day 18 (1 DPI for EDIM), the DRI group had lower 
viral shedding than that in animals only infected with EDIM at 
day 17, without the previous infection with SA11 (171.46% com-
pared with the EDIM group’s viral shedding, p < 0.05). However, 
in this case, all the supplemented groups showed higher viral 
clearance than the DRI group (1,272.39% for the HBC group; 
474.25% for the PRE group; 302.86% for the PRO group; and 
434.34% for the SYN group), but without statistical significance 
due to the high interindividual variability found.
DTh response
The DTH response was studied on day 28, after 24 and 48 h post-
ear priming. At 24 h, the REF group obtained an ear thickness 
increase of 0.86 ± 0.46. The EDIM group (without the first infec-
tion with SA11) had an increase of 1.13 ± 0.52 (p < 0.05 vs. REF); 
however, the DRI group had similar values to those obtained from 
the REF group (0.71 ± 0.57). None of the supplemented groups 
showed statistically significant differences (0.86 ± 0.70 for HBC; 
1.91 ± 0.77 for PRE; 0.88 ± 0.64 for PRO; and 2.00 ± 0.77 for SYN 
group) with respect to the REF or DRI groups. The DTH response 
at 48 h followed a similar pattern.
Ex Vivo-specific anti-rV antibody 
Production
The ability of sensitized cells to produce specific Ig in the systemic 
(spleen) and mucosal (MLN) compartments has been studied 
after dietary treatment in animals only infected with SA11 or 
double-infected with SA11 and EDIM (Table 3). It can be seen 
that none of the single infections (SA11 at day 6 alone or EDIM 
at day 17 alone) were able to increase this variable of spontane-
ous ability to have natural defenses against the RV. However, the 
double infection induced an increase in the number of Ig-SC in 
the systemic compartment (p < 0.05). This did not happen in the 
mucosal compartment.
Focusing on the first infection (Table 3), all dietary interven-
tions induced an increase in the anti-RV Ig-SC with respect to the 
REF and SA11 groups, with the exception of the PRE on the MLN 
(p < 0.05 vs. SA11 group). A different pattern was found when 
animals were subjected to a double infection (Table 3). All dietary 
interventions downmodulated the Ig-SC number (p < 0.05) and 
therefore had an immune response similar to that of the non-
infected group.
Ex Vivo cytokine Production
The levels of ex vivo production of IFNγ by splenocytes after 
72 h were under the limit of detection in some groups. This was 
the case for the REF, DRI, and HBC (double-infected) groups 
(Figure 5A). However, the groups with a single infection, either 
SA11 at day 6 or EDIM at day 17, had cells that were capable of 
responding to the challenge and produced a certain amount of 
IFNγ. As regards the dietary interventions in single-infected ani-
mals, none of them greatly modified the levels of IFNγ induced 
by SA11 in in vitro stimulation, with the exception of the SYN 
group, which had twice those levels. After the second infection, 
although the DRI group had no IFNγ, all the pre- and probiotic 
interventions induced detectable levels, with the highest effect 
being in the SYN group again (Figure 5A).
IL-4 was also studied (Figure 5B). This cytokine was produced 
at low levels in cells from the REF group and was not detected 
after double infection (DRI group). However, the single infections 
did induce IL-4, similarly to that described for IFNγ (p < 0.05). 
The pre- and probiotic supplementations did not significantly 
modify the IL-4 production in SA11-infected animals, although 
the PRO and SYN groups showed higher levels (Figure 5B). After 
the double infection, the DRI group had no detectable IL-4, and 
nor did the HBC group, but the rest of the interventions induced 
the production of this cytokine, with the SYN group being the one 
with the highest production (Figure 5B).
FigUre 5 | Cytokine ex vivo production in single- and double-infected 28-day-old animals. (a) IFNγ, (B) TNFα, (c) IL-4 and (D) IL-10 cytokine concentrations. 
Results are expressed as mean ± SEM (n = 3–12 animals/group). Statistical significance: *p < 0.05 vs. REF, #p < 0.05 vs. SA11 or DRI (first and second infection, 
respectively). Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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As for TNFα, the levels of this cytokine were low in the REF 
group and the infection with either SA11 or EDIM alone induced 
an increase of up to four times (Figure 5C, p < 0.05). However, 
this increase was not observed in the DRI group. The dietary 
interventions did not affect the production of TNFα when SA11 
infection was performed alone, but they did induce an increase 
in such levels after a double infection when compared with DRI 
group levels (Figure 5C, p < 0.05).
Finally, there was no statistically significant difference between 
the IL-10 ex vivo production in the REF group, single-infected 
groups, and the DRI group (Figure 5D). A non-significant increase 
in the IL-10 production could also be seen due to the supplements 
in double-infected animals with respect to the DRI group.
Mucosal iga and serum igM global 
antibody levels
The mucosal immune status was studied in the animals with 
different types of infections and after receiving the products at 
the first and second end point. The total IgA was measured in 
intestinal wash after the first (day 16) and second (day 28) infec-
tion. On day 16, the SA11 group had 2,367.73 ± 689.70 arbitrary 
units (AU) of total IgA in GW and all dietary interventions 
increased this value, although only the PRE and SYN groups 
were significantly different (7,411.41 ±  3,714.63  AU for HBC; 
14,236.02 ±  3,855.70  AU for PRE; 2,998.60 ±  1,678.05  AU for 
PRO; and 27,800.00 ± 5,809.04 AU for the SYN group). On day 
28, the DRI group displayed values of 923.94 ± 112.22 AU of total 
IgA in GW, which was similar to this antibody’s levels in the SA11 
group at this age (1,003.60 ± 178.12), but higher than those in the 
EDIM group (451.90 ± 66.85, p < 0.05). In this case, the supple-
ments did not affect the IgA levels, with the exception of the HBC 
and the PRO groups, which had lower levels (460.14 ± 97.29 AU 
for HBC; 1,193.12 ± 131.11 AU for PRE; 591.59 ± 96.51 AU for 
PRO; and 631.49 ± 142.09 AU for SYN group).
In addition, the systemic immune status in such early life 
was also assessed by evaluating the total IgM measurement in 
serum after the first (day 16) and second infection (day 28). 
Age influences the production of this Ig, with values on day 28 
being twice as high as those at day 16 (Table S1 in Supplementary 
Material). On the other hand, the infections did not influence 
these values, and only the SYN diet was able to increase the IgM 
titers (p < 0.05) both at day 16 and day 28 with respect to the rest 
of the groups (Table S1 in Supplementary Material).
TaBle 4 | Specific anti-rotavirus antibodies in gut wash (GW) (total Ig) and serum (total Ig and IgM) from 16- and 28-day-old rats.
reF Dri hBc Pre PrO sYn
Day 16 GW Ig 14.85 ± 3.00 7.14 ± 2.43 6.09 ± 1.82* 13.05 ± 3.92 22.97 ± 6.94 23.45 ± 6.75
Serum Ig 1,624.96 ± 71.22 954.78 ± 155.66* 1,268.11 ± 195.28 1,234.32 ± 193.24 980.19 ± 68.19* 1,537.90 ± 64.49#
IgM 442.64 ± 41.28 388.02 ± 61.10 540.19 ± 68.59 419.68 ± 47.22 500.79 ± 58.51 451.96 ± 99.81
Day 28 GW Ig 27.37 ± 27.25 54.88 ± 35.31 109.08 ± 56.77 35.24 ± 23.21 71.58 ± 50.20 31.99 ± 31.82
Serum Ig 1,055.90 ± 81.64 1,048.51 ± 84.14 1,510.03 ± 276.22 883.89 ± 77.37 800.36 ± 64.38*,# 1,041.69 ± 89.86
IgM 575.59 ± 28.71 711.26 ± 95.59 1,067.42 ± 196.08* 700.77 ± 71.57 774.38 ± 89.41 746.52 ± 75.46
Results are expressed as mean ± SEM (n = 6–12 animals/group).
Statistical significance: *p < 0.05 vs. REF; #p < 0.05 vs. DRI.
Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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anti-rV ig in the intestine and serum
Specific anti-RV antibodies were quantified in intestinal wash 
from 16- and 28-day-old rats as well (Table 4).
At mucosal level, the DRI group at day 16 of life had similar, 
or even lower, titers of anti-RV antibodies to the REF group. 
Although no statistical significance was found on day 16, the 
pre- and probiotic supplementations showed a tendency to 
increase these levels. In terms of the second infection, there was 
an age-dependent increase in these titers, as can be seen on day 
28 of life when compared with day 16, but again without sig-
nificant differences between the REF and DRI groups. The group 
of animals only infected with EDIM had 119.27 ± 50.14 AU of 
anti-RV antibodies, slightly higher than that of the DRI group 
(with a previous RV infection). The nutritional interventions did 
not affect this variable either (Table 4).
Specific anti-RV antibodies were quantified in serum (total 
and IgM) from 16- and 28-day-old rats (Table 4). The REF group 
already had levels of anti-RV Ig that were even higher (p < 0.05) 
than those after SA11 infection at day 6 or EDIM infection at 
day 17 (682.43 ± 28.86 and 1,154.41 ± 116.44 AU, respectively). 
The EDIM infection alone and the DRI behaved quite similarly. 
Interestingly, the titers did not increase with age, and even 
decreased in some cases. With regard to the dietary interventions, 
just the PRO and SYN groups modified the anti-RV Ig (p < 0.05). 
The PRO diet downmodulated the titers at both time points, and 
the SYN diet up-modulated them on day 16 (Table 4).
Specific anti-RV IgM followed a similar pattern to total IgM in 
serum. Levels increased with age, and REF values were similar to 
those of infected animals, in this case with the exception of EDIM 
alone (905.03 ± 87.80, p < 0.05 vs. REF group). The HBC seemed 
to potentiate the production of these antibodies (p < 0.05 on day 
28), but this was not clear with the other dietary interventions.
cytokine levels in gW
Cytokines in GW samples at the end of the study (day 28) were 
determined. In healthy animals (REF group), IFNγ was not 
detected. However, all the infected animals (double-infected 
with SA11 and EDIM) had quantifiable amounts of this molecule 
(Figure 6A). All dietary interventions also induced higher levels 
than the DRI animal; however, only HBC achieved statistical 
significance.
IL-4 was detected in all samples from the REF and infected 
groups (Figure 6B). Although IL-4 levels were similar in the REF 
and DRI groups, the animals with dietary interventions displayed 
higher values and were statistically different to those in the REF 
(p < 0.05) and DRI groups (p < 0.05), with the exception of the 
SYN group.
TNFα is also a cytokine measured in this fluid that was not 
detected in all samples. Thus far, none of the samples in the REF, 
DRI, and HBC groups had detectable levels. All dietary interven-
tions with pre- or probiotics induced detectable levels of TNFα 
(Figure 6C).
IL-10 was found in all samples at levels ranging from 40 to 
300 pg/mL. The REF group had values of ~40 pg/mL, and these 
values were increased by up to four times in the DRI group 
and even more due to the HBC treatment. All infected groups 
displayed significantly higher values than non-infected animals, 
with only those animals from the PRO group being significant vs. 
the DRI group (Figure 6D).
gene expression changes
The gene expression of several genes involved in immune response 
and intestinal barrier was studied, as can be seen in Table 5.
As regards TLRs, neither TLR2 nor TLR4 were modified by 
DRI or HBC interventions. However, the four dietary interven-
tions modulated this pattern similarly. The dietary treatments with 
PRO or SYN significantly increased TLR2 levels (252.19 ± 62.42 
and 678.41 ± 77.09, respectively) (p < 0.05) with respect to REF or 
DRI animals (100.00 ± 17.14 and 99.21 ± 55.51, respectively). By 
contrast, TLR4 gene expression (Table 5) was reduced by all four 
interventions when compared with the REF group (p <  0.05), 
suggesting a downmodulatory action on the activation of the 
immune response.
The analysis of IL-4 revealed that there was very low expres-
sion in this tissue and conditions (in most of the samples it was 
not detected and in some others it was detected with a Ct > 38). 
However, in the low number of samples in which it was detected 
the results showed that the DRI group had 143.74 ±  63.91% 
(compared with the 100% in the REF group), whereas the HBC and 
the PRO diets reduced by up to 38.33 ± 14.44 and 29.10 ± 7.23%, 
respectively. The gene expression of IFNγ in this intestinal tissue 
was even lower, with only some samples with quantifiable expres-
sion in the REF, DRI, and HBC groups, but with Ct > 39.
Occludin and claudin-2 were also evaluated and similarly to 
the other genes studied, the gene expression of both TJ proteins 
was not affected in either the DRI or the HBC animals. However, 
the dietary treatments induced a decrease in the occludin 
gene expression (p < 0.05) and an increase in the claudin gene 
TaBle 5 | Small intestine gene expression from 28-day-old rats.
Tlr4 Occludin il-10 TgFβ
REF 100.00 ± 19.46 100.00 ± 17.14 100.00 ± 17.65 100.00 ± 15.79
DRI 87.09 ± 38.38 119.48 ± 15.28 103.86 ± 28.57 101.58 ± 5.95
HBC 70.58 ± 16.75 80.13 ± 25.88 145.85 ± 47.41 106.09 ± 16.06
PRE 59.86 36.76 ± 12.00*,# 135.03 ± 62.54 102.54 ± 30.13
PRO 39.33 ± 7.00* 65.67 ± 12.67*,# 148.34 ± 74.31 62.85 ± 10.34*,#
SYN 39.10 ± 15.88* 50.35 ± 8.87*,# 92.23 ± 6.41 48.14 ± 3.16*,#
Results are expressed as mean ± SEM (n = 6 animals/group).
Statistical significance: *p < 0.05 vs. REF, #p < 0.05 vs. DRI.
Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine 
colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
FigUre 6 | Cytokine levels in gut wash from 28-day-old rats. (a) IFNγ, (B) TNFα, (c) IL-4 and (D) IL-10 cytokine concentrations. Results are expressed as 
mean ± SEM (n = 3 animals/group). Statistical significance: *p < 0.05 vs. REF, #p < 0.05 vs. DRI. Groups: REF, reference; DRI, double rotavirus infected; HBC, 
hyperimmune bovine colostrum; PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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expression, which was only significant in the case of the SYN 
group (1,115.81  ±  360.78, p  <  0.05). Mucin gene expression 
was not modified by either the infective process or the dietary 
interventions.
Finally, IL-10, TGF-β, and foxp3 were also quantified. The gene 
foxp3 was not detected in any of the analyzed samples (data not 
shown). However, the cytokines IL-10 and TGF-β were detectable 
(Table 5). In the case of IL-10, its gene expression was very low 
and it was unaffected by the infection or the dietary supplementa-
tions. By contrast, the gene expression of TGF-β was not affected 
in the DRI or HBC groups, or in the PRE group, but PRO and 
SYN induced a significant reduction (p < 0.05).
scFa Production
The main SCFAs (acetic, propionic, and butyric), but also lactic 
and formic acids, were quantified in the fecal samples of 21- and 
28-day-old rats. Overall, total and specific SCFAs in the REF 
group were not statistically modified due to RV infections or 
dietary interventions, except for an increase in acetic acid in 
the DRI group at day 28 (5.95 ±  2.72 vs. 1.83 ±  0.16 in REF, 
p < 0.05) (Figure 7).
DiscUssiOn
Rotavirus is a major cause of acute and severe gastroenteritis in 
children, and although appropriate rehydration is the therapeutic 
intervention of choice, the introduction of other strategies such as 
prebiotics and probiotics is of interest (11). In this regard, by using 
the double-RV infection model in neonatal rats, which is more 
similar to the clinical reality than a simple infection model, this 
study has evidenced the potential of different microbial modula-
tor products of importance in early life to modulate first infection 
and the host defenses for a better second infection resolution. It 
FigUre 7 | Short-chain fatty acid concentrations in feces from the different experimental groups at days 21 and 28. Results are expressed as mean ± SEM 
(n = 3–7 samples/group). Statistical differences: *p < 0.05 vs. REF. Groups: REF, reference; DRI, double rotavirus infected; HBC, hyperimmune bovine colostrum; 
PRE, prebiotic; PRO, probiotic; SYN, synbiotic.
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should be taken into account the importance of the bioactive fac-
tors present in breast milk in protecting the pups from infection. 
Although this nursing effect is not avoided during first infection, 
it was solved in the second infection by early weaning the animals 
the previous day of the second virus inoculation.
The model used has the appropriate features expected. Thus 
far, the first infection has induced mild diarrhea, which is very 
similar to what was found in previous studies (with the simple 
SA11 infection model) (23, 43, 47). The incidence, duration, and 
severity of diarrhea, and the fecal weight results from the DRI 
group after SA11 infection in this study, have been consistent 
with those in the RV group in previous studies (43). In addi-
tion, changes in pH and temperature have been associated with 
the first viral infection. Moreover, as expected, no diarrhea or 
changes in pH and temperature have been observed after the 
second infection, if the first is performed, due to the maturity of 
the immune system. With regard to other variables studied, the 
maximum viral shedding of SA11 was on 1DPI after both the 
first and second infections. Furthermore, a presence of specific 
antibodies at the systemic and at the intestinal level was found at 
day 14 in the previous study (43) as well as at day 16 in this one, 
increasing with age in both studies.
Several RV-infection animal models are already available, but 
most of them are single-infection models, which do not reflect the 
multiple reinfections that humans have during early life. Overall, 
although the limitation that no diarrhea is displayed in the second 
infection in this model, the RV double-infection rat model is 
suitable for studying the influence of interventions performed to 
regulate first infections (e.g., by vaccination, therapeutic agents, or 
nutritional supplementation) on the onset of a future reinfection, 
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which so often occurs in humans. In addition, and regarding the 
interventional approach performed, a current limitation of this 
study is that the bacterial strain arrival to the gut was not studied, 
although it has been previously demonstrated in several studies 
in all humans, mice, and rats (55–57).
To evaluate the effect of modulating the first infection on 
the outcomes in the second viral infection a positive protection 
control (HBC) was used. A complete protection from diarrhea 
was achieved after the first infection with SA11 and it avoided 
the increase in fecal weight induced by RV in the acute phase 
of the disease. However, it increased the viral shedding after the 
second infection with EDIM, but still allowed the development of 
immune response, among other changes. These results, which are 
in line with those observed in other studies (25, 26), allow us to 
confirm its suitability as a protective control in this design.
As the second infection did not induce diarrhea we have to 
focus on first infection results to evaluate the effect of the prebiotic 
and probiotic intervention on the control of clinical symptoms. 
Overall, all diets seem to have a protective role somehow in some 
of the variables analyzed. On the one hand, the scGOS/lcFOS 
mixture, at the dose used here, as in previous studies (43), has a 
masking effect on the fecal consistency, which is one of the main 
limitations of this compound. This effect, also present in the SYN 
intervention, induced a softened stool consistency, which is not 
dependent on the presence of the virus. However, the scGOS/
lcFOS supplementation was able to decrease the incidence and 
severity of diarrhea, or at least, the impact on the fecal consist-
ency was not added to that derived from the gastroenteritis, as 
is observed after normalization of the results. These changes in 
stool consistency, bringing it closer to breastfed infants (58, 59), 
are thus a desirable effect. The PRO was the one with the clear-
est effect. B. breve M-16V reduced the incidence, duration, and 
severity of the experimental diarrhea, effects that seem to be 
hidden by the prebiotic addition when the synbiotic is formulated. 
These results are in line with those obtained in the previous study 
(43). In the same vein, the increase in the fecal weight seems to 
be a clear indicator of the incorporation of water in the total fecal 
content (47, 60) and therefore it has been used as an objective 
marker of diarrhea in this model. All nutritional interventions 
here avoided the fecal weight increase associated with the acute 
phase of diarrhea. The effects due to scGOS/LcFOS and B. breve 
M-16V are in line with those obtained in the previous study (43).
In addition, fecal pH and body temperature were measured 
in this study, as new non-invasive clinical markers. The fecal pH 
only changed during the first infection. This may be because of 
the electrolyte imbalances caused by the diarrhea (5). Li et al. also 
observed an increase in pH in the colonic content of RV-infected 
piglets when compared with non-infected animals (42). The 
dietary interventions avoided the RV-induced increase of fecal 
pH. On the other hand, the rectal temperature increased after the 
first RV inoculation with SA11 in the DRI group, but not after 
the second inoculation with EDIM. However, the EDIM inocula-
tion on day 17 as a primary infection was able to induce fever on 
that day, so this variable shows a differential pattern between the 
single and the double-infection model, suggesting that the first 
infection allows the setting up of mechanisms involved in second 
infection control. Few studies have evaluated body temperature. 
For example, Parreño et al. measured it after the first infection of 
a double-infection calf model and observed fever (25). The HBC 
and the dietary interventions with pre- and probiotics showed a 
similar behavior to the DRI group, which means that, although 
the interventions conferred protection during the first RV inocu-
lation, this infection was still able to allow mechanisms to control 
the second infection.
Viral shedding has been suggested as a marker of protection 
where higher presence of the virus in feces would mean higher 
elimination. However, this statement is not fully applicable in our 
model and interventions, because we have demonstrated that the 
scGOS/lcFOS mixture has a high capacity to bind the RV and 
block its infection but at the same time did not allow the virus to 
be detected by our ELISA technique (43). In accordance with this, 
the peak of viral elimination after the first inoculation with SA11 
was substantially reduced in the groups supplemented with 
scGOS/lcFOS alone or in combination with the B. breve M-16V. 
By contrast, a similar viral shedding was observed in the group 
supplemented with the probiotic when compared with the DRI 
group after the first inoculation, as happened in the previous 
study (43). However, after the second inoculation, all dietary 
supplemented groups, even that with the scGOS/lcFOS mixture, 
shed a higher viral load than the DRI group, maybe as a conse-
quence of the protection conferred during the first infection, and 
in line with the results obtained with HBC (26).
With regard to humoral immune response, it is described 
that the antibody-mediated immunity against RV involves both 
systemic and mucosal responses (6). This is a limitation of rodent 
models of RV infection because diarrhea only appears on early 
suckling due to the fact that their naturally acquired immune 
response against the virus is already highly effective in the wean-
ling period (47, 61). In this context, the presence of specific anti-
bodies in the model used herein did not enable clear observation 
of the development of protection against the virus after the first 
infection (although, on day 16, the animals were already weaned, 
the maternal influence can still be of importance on this day), or 
after the second infection. None of the supplementations showed a 
clear effect on the antibody titers either. These results contradict 
those obtained in the previous study (43), in which scGOS/lcFOS 
alone or in combination with the B. breve M-16V supplementa-
tion in early life increased local and systemic humoral response 
against the virus, suggesting a modulatory role of this interven-
tion in the maturation of the immune system. However, some 
enhancing effects on the humoral immune status associated with 
certain dietary interventions (i.e., B. breve M-16V on systemic 
IgM) are in line with our results related to the supplementation 
with B. breve M-16V in the previous study (43) and those derived 
from other probiotics such as LGG or Lactobacillus acidophilus 
NCFM, which increased IgM in pigs and infants after this type 
of infection (62–64). In fact, a previous study was conducted to 
demonstrate the high immunomodulatory potential of B. breve 
M-16V in early life using the rat as a model of immune develop-
ment in which the intestinal IgA synthesis was enhanced (65).
By contrast, the ex vivo Ig production determination allowed 
a differential response to be observed between the single infec-
tions and the double-infection model. The effect of the nutritional 
interventions could be evaluated, and they even enhanced the 
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immune response against the first virus, while a downmodulation 
was observed in the second infection. This may indicate that the 
dietary reinforcement during the first infection at cellular level 
may lead to higher protection in the second one and therefore 
intense humoral immune response is not required. An increase 
in IgA-SC or IgG-SC was observed in other studies, when LGG or 
L. acidophilus NCFM were administered in pigs vaccinated and 
challenged with HRV (human rotavirus) (62, 64).
In terms of cellular response, several immune variables have 
been evaluated, such as the DTH response and the production 
of several cytokines. In particular, the DTH response has been 
described as being different depending on the model used in this 
context but it may reflect the primed cells before the challenge. 
Other studies showed a response after an infection at day 17 in 
mice and later suppression after a reinfection in mice who had 
received a primary infection before (26, 66), which are line with 
our study and did not allow clear conclusions to be drawn.
Focusing on cell mediators, RV triggers an immune response 
in the host, which is responsible for the timely resolution of the 
disease and the subsequent acquisition of immunity against 
reinfections. The cytokines produced act as mediators of immune 
and inflammatory responses, leading to the recruitment and 
activation of different populations of leukocytes, which ulti-
mately produce cytokines in response to and against the RV. The 
potential part played by cytokines in the cellular response to RV 
has highlighted the importance of this aspect of host defense. The 
determination of intestinal cytokines during the peak of the diar-
rheic process, when it is already solved, or after in vitro challenge, 
could give an insight into the state of immune activation.
A differential pattern between the single infection and the double-
infection model was also found in the ex vivo cytokine production, 
meaning that the first infection causes different immune response 
in the second infection. In this case, the dietary interventions 
enhanced the production of these cytokines not only when only one 
infection occurred, but also in the double-infected animals. This 
effect was observed for all Th1 (IFNγ), Th2 (IL-4), pro-inflammatory 
(TNFα), and anti-inflammatory (IL-10) cytokines. The promotion 
of these cytokines are in agreement with the fact that Th1 (IFN-γ)/
Th2 (IL-4) cytokines initial release may participate in the inhibition 
of viral replication by promoting cell-mediated immunity whereas 
IL-10 could exert diverse roles in the pathogenicity and immunity 
against RV infection (67). In this line, several probiotics have shown 
the ability to enhance cytokine production in vitro (68). Wen et al. 
(64, 69) found an increase in IFNγ production by T-cells and a 
decrease in IL-10 production by Treg in pigs vaccinated with HRV 
and administered with LGG. On the other hand, the intestinal wash 
is a fluid with components from the mucosa layer that reflects the 
activity of the intestine. Cytokines from intestinal wash were only 
determined in double-infected animals and followed a similar pat-
tern to the cytokines produced ex vivo.
With regard to gene expression, TLR2 and TLR4 genes were 
selected to be studied because TLR2 genes recognize, among 
other ligands, the cell-wall components such as peptidoglycan, 
lipoteichoic acid and lipoprotein from Gram-positive bacteria, 
whereas the latter bind to the bacterial lipopolysaccharide, which 
is the major structural component of the outer wall of all Gram-
negative bacteria and a potent activator of the immune system. 
IFNγ and IL-4 were the selected cytokines involved in the Th1 
and Th2 responses, respectively, for this assay. Besides immune 
molecules, others such as those from the TJ, which have been 
described as being modulated by probiotics in vitro and in vivo 
elsewhere (70), were also quantified. Mucin is a high-molecular-
weight and heavily glycosylated protein produced by intestinal 
epithelial tissues to form a gel that acts in lubrication, cell signaling 
or in the formation of chemical barriers (70). Finally, molecules 
involved in regulatory and tolerogenic response, such as IL-10, 
TGF-β, and FoxP3, were also measured.
No differences in the levels of these molecules in the double-
infected group (DRI) and HBC treatment were observed at day 
28. This may indicate that at this age, more than 2 weeks after the 
second viral infection, few effects if any due to the RV infection 
persisted. However, the effect of the supplementation with some 
of the products seems to still be evident. On the one hand, the 
presence of prebiotics and probiotics (or both) in the gut may 
increase the proportion of Gram-positive bacteria (i.e., bifidobac-
teria and/or lactobacilli) and therefore the TLR in charge of its 
detection too, the TLR2. By contrast, Wang et al. (71) did not find 
a significant increase in TLR2 gene expression in the intestinal 
mononuclear cells of pigs which had been RV vaccinated and 
administered with LGG, but they did find an increase in TLR4 
gene expression. Other studies have observed the ability of some 
probiotics to improve the barrier function (70), which is not clear 
in the present work because whereas occludin is downmodulated, 
claudin expression is enhanced. The results obtained here also 
suggest that the dietary interventions maintain or even down-
modulate the regulatory and tolerogenic immune response, in 
disagreement with Wang et  al. (71), who found an increase in 
IL-10 gene expression. These differences may highlight the influ-
ence of both the experimental model used and the strain studied.
Finally, the SCFA concentration found in feces was very low 
in all groups, which also happened in the previous study (43) and 
was in contrast with the increase in the SCFAs seen in other stud-
ies with GOS or GOS/FOS (72–74). This lack of positive outcome 
in the fecal samples analyzed as being due to the prebiotic supple-
mentation may be a reflection of their high absorption in the colon 
(75), which might therefore affect their content in fecal samples.
In conclusion, scGOS/lcFOS and B. breve M-16V supplemen-
tation in early life is able to ameliorate RV-induced gastroenteritis 
whereas it allows the host to elaborate its own immune responses 
that would be of importance in controlling a second infection. 
The results obtained help in identifying key prebiotics and 
probiotics with modulatory effects on the maturation of defense 
mechanisms of the newborn, especially in the prevention and 
treatment of RV infections. Further studies are needed to gain a 
deeper insight into the effects of these compounds, and to under-
stand if such effects could be transmittable from the rat model 
to humans. Moreover, the timing and dosage of administration 
of these microbial modulator compounds are also to be further 
determined. All these determinations may lead to conclusions 
being drawn about whether they are suitable for strengthening 
the mechanisms of defense of the newborn and whether this 
scientific knowledge generated by these results at a preclinical 
level could permit, at midterm the incorporation of these types 
of functional supplements in infant formulas.
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